August 2020 – Immunotherapy
This special issue of CONQUER magazine is about a very innovative way of treating cancer. For many decades, we have been using surgery, chemotherapy, and radiation therapy as the main treatments for different types of cancer.
By Laurie Adami
I have had a long and intricate dance with a blood cancer. It began in 2006, when I was 46 years old, my son was in kindergarten, and I was president of a Los Angeles–based software company.
By Dana Taylor
Our natural immune system is made of cells and other substances that help our body to defend itself by fighting foreign invaders, such as contaminated substances in the air and viral or bacterial infections, as well as to destroy abnormal cells, including cancerous cells.
Immunotherapy with Libtayo Prolongs Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
New results of a study presented at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO) show that use of immunotherapy prolongs survival for patients with advanced or metastatic (spreading) cutaneous squamous-cell carcinoma (CSCC).
Libtayo Reduces Pain, Improves Quality of Life in Patients with Advanced Cutaneous Squamous-Cell Carcinoma
New data presented at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO) showed that treatment with the relatively recently approved immunotherapy Libtayo (cemiplimab), a PD-1 inhibitor, led to lasting reductions in pain and improved quality of life in patients with advanced cutaneous squamous-cell carcinoma (CSCC) in addition to improved survival without disease progression.
Immunotherapy plus Chemotherapy a New Standard of Care for Patients with Extensive-Stage Small-Cell Lung Cancer
By Phoebe Starr
Patients with a type of lung cancer called extensive-stage small-cell lung cancer now have a new first-line treatment option with immunotherapy in combination with chemotherapy. This new combination has shown to improve survival for these patients, who don’t have many treatment options and whose prognosis is less than 5 years.
New results presented at the 2020 meeting of the American Society of Clinical Oncology suggest that there is a new standard of care for the first-line treatment of some patients with advanced colorectal cancer.
By Phoebe Starr
Using the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, prolongs the time without disease progression in patients with relapsed (coming back) or refractory (not responding to treatment) classical Hodgkin lymphoma compared with the current standard of therapy of Adcetris (brentuximab vedotin), an antibody–drug conjugate.
Results 1 - 9 of 9